Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Source: Alfacell Press Release
Alfacell Corporation is currently conducting a Phase III-b clinical trial of Onconase® in patients with unresectable malignant mesothelioma. Alfacell has developed Onconase® using its proprietary ribonuclease (RNase) technology. The treatment compound is a protein derived from the leopard frog and has been shown in laboratory and clinical trials to attack cancer cells while ignoring healthy cells.
Alfacell's latest announcement is an update on the performance status of the trial. Enrollment in this trial will close on September 30, 2007. If the results of the trial are positive, Alfacell will then submit the final stages of the application for Onconase's New Drug Application (NDA).
Alfacell Corporation is currently conducting a Phase III-b clinical trial of Onconase® in patients with unresectable malignant mesothelioma. Alfacell has developed Onconase® using its proprietary ribonuclease (RNase) technology. The treatment compound is a protein derived from the leopard frog and has been shown in laboratory and clinical trials to attack cancer cells while ignoring healthy cells.
Alfacell's latest announcement is an update on the performance status of the trial. Enrollment in this trial will close on September 30, 2007. If the results of the trial are positive, Alfacell will then submit the final stages of the application for Onconase's New Drug Application (NDA).
Labels: mesothelioma
posted by Belluck & Fox at
9:42 AM
© Belluck & Fox, L.L.P. All rights reserved.
